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Abstract. Drug delivery in the brain is limited by slow drug diffusion in the brain tissue. This study tested
the hypothesis that ultrasound can safely enhance the permeation of drugs in the brain. In vitro exposure
to ultrasound at various frequencies (85 kHz, 174 kHz, and 1 MHz) enhanced the permeation of tritium-
labeled molecules with molecular weight up to 70 kDa across porcine brain tissue. A maximum
enhancement of 24-fold was observed at 85 kHz and 1,200 J/cm
2. In vivo exposure to 1-MHz ultrasound
further demonstrated the ability of ultrasound to facilitate molecule distribution in the brain of a non-
human primate. Finally, ultrasound under conditions similar to those used in vivo was shown to cause no
damage to plasmid DNA, siRNA, adeno-associated virus, and fetal rat cortical neurons over a range of
conditions. Altogether, these studies demonstrate that ultrasound can increase drug permeation in the
brain in vitro and in vivo under conditions that did not cause detectable damage.
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INTRODUCTION
The development of therapies to treat brain diseases
including brain cancer has been limited by the failure of
efﬁcient drug delivery into the brain due to the blood–brain
barrier (BBB) (1). Several approaches have been developed
to successfully bypass the BBB and deliver drugs into the
brain, but their ability to increase the depth of drug
penetration or distribution within the brain is still limited
(1). Controlled release devices including plastic drug reser-
voirs (2), implantable pumps (3), and biodegradable polymers
(4,5) have been designed to provide drug diffusion for an
extended time, but diffusion distance has been limited to less
than a few millimeters from the point of drug administration
due to very low diffusivity (6,7). Drug diffusion also requires
a high concentration gradient, and such high drug concen-
trations often lead to neuronal toxicity (8).
Convection-enhanced delivery (CED) provides a convec-
tive driving force to ﬂow drugs deeper into tissue (9–11). CED
has been shown to be effective for delivering large molecules,
including DNA and viral gene therapy vectors. Clinical trials
have been conducted to apply CED to the treatment of brain
cancer (11). However, poor drug distribution limits this
technique due to the considerable resistance to ﬂow within
densely packed brain tissue. To reach larger volumes in the
human brain, it is often necessary to infuse drugs for longer
periods oftime, i.e., fromhoursto days, makingthisapproach
impractical. Overall, current methods have chieﬂy focused on
strategies to deliver drugs into the brain by breaching the
BBB but have been limited in their ability to increase the
depth of drug penetration or distribution within the brain.
In this study, we propose the hypothesis that ultrasound
(US) can facilitate drug distribution in the brain. US-based
drug delivery applications are increasingly being tested, and
several successful studies in animals and humans have been
demonstrated, with a few applications already entering in the
clinical setting (12). US has been shown to increase drug
transport into and across a number of tissues, including skin
(13,14), kidney (15), heart (16), and blood clots (17). Of
particular interest, US-mediated disruption of the BBB has
been previously shown to signiﬁcantly enhance drug delivery
to the brain (18,19). It was shown that using low-energy
focused US pulses combined with an US contrast agent could
reversibly disrupt the BBB in the US-targeted regions of the
brain without adverse effects in the brain tissue. A variety of
therapeutic agents including chemotherapeutic drugs and
antibodies were shown to be effectively delivered into the
brain with US exposure at frequencies suitable for trans-
cranial usage (19,20). The mechanism is believed to involve
ultrasonic non-thermal bioeffects, particularly induction of
acoustic cavitation and its disruptive interactions with the
brain vasculature to facilitate increase in blood vessel
permeability to drug molecules (21). Other cellular-level
studies exploring changes in microscopic histological features
Ying Liu and Sumit Paliwal contributed equally to this study.
1School of Chemical and Biomolecular Engineering, Georgia Insti-
tute of Technology, Atlanta, Georgia 30332-0100, USA.
2Department of Chemical Engineering, University of California,
Santa Barbara, California 93106, USA.
3 Department of Neurological Surgery, Brain Tumor Research
Center, University to California, San Francisco, California 94103,
USA.
4CytoDome, Inc, Atlanta, Georgia 30342, USA.
5To whom correspondence should be addressed. (e-mail: samir@
engineering.ucsb.edu; prausnitz@gatech.edu)
DOI: 10.1208/s12249-010-9458-0
AAPS PharmSciTech, Vol. 11, No. 3, September 2010 (# 2010)
; published online 8 June 2010
1005 1530-9932/10/0300-1005/0 # 2010 The Author(s). This article is published with open access at Springerlink.comof the sonicated blood vessels have also been conducted (22).
However, a systematic study investigating the effects of US on
the increase in tissue permeability and, therefore, increased
distribution of drugs in the brain at a macroscopic tissue-level
has not been performed. Furthermore, in the context of brain
drug delivery, the effects of US exposure on changes in the
bioactivity of various therapeutic agents have not been
evaluated.
In this study, we show that US, applied at various
frequencies and energy densities, can signiﬁcantly enhance
the transport and distribution of several molecules across
both normal and tumor brain tissue in vitro and facilitate the
distribution of gadolinium-encapsulated liposomes in targeted
regions of the brain in vivo. We also test the hypothesis that
US conditions suitable for increased brain delivery do not
damage the functionality of drugs and delivery carriers
including plasmid DNA, siRNA, and adeno-associated virus
and do not reduce the viability of cortical neurons and the
integrity of brain tissues. These studies indicate that US-
assisted drug delivery to the brain offers a promising treat-
ment strategy which effectively addresses the issue of limited
penetration of drugs post-delivery within the brain tissue.
MATERIALS AND METHODS
In Vitro Brain Delivery
Experimental setup. Excised porcine brain tissue was
procured in frozen form (LyChron LLC, Mountain View,
California, USA), stored at −80°C, and later defrosted at
room temperature prior to the experiment. Cylindrical
sagittal sections of brain (1.8 cm in diameter and 2 mm in
thickness) were carefully cut and mounted onto a custom-
made diffusion cell consisting of a donor and a receiver
compartment (Fig. 1) with a cross-sectional area of 2.54 cm
2.
The receiver compartment was ﬁlled with a sodium/potassium
phosphate-buffered saline (PBS; Sigma-Aldrich, St. Louis,
Missouri, USA) prepared in MilliQ® ultrapure water
(Millipore, Billerica, Massachusetts, USA) consisting of
0.01 M phosphate and 0.137 M NaCl. Separate solutions of
different
3H-labeled model molecules, including water,
mannitol, inulin, and dextran (70 kDa; ART-194A, ART-
118, ART-278, and ART-215; American Radio Chemicals, St.
Louis, Missouri, USA) and bischloroethyl-nitrosourea (BCNU;
MT-1644, Moravek Biochemicals, Brea, California, USA), were
prepared in PBS at a concentration of 1 µCi/mL and ﬁlled into
the donor compartment in separate experiments.
Frozen human brain 9-L tumors grown under rat skin
with Institutional Animal Care and Use Committees
(IACUC) approval were kindly provided by the Brain Tumor
Research Laboratory at the Johns Hopkins University.
Similar to porcine brain tissue, tumor tissues were also cut
to 1.8 cm in diameter and 2 mm in thickness and studied as
described above.
US application. Three custom-built, non-focused, piezo-
electric transducers (CytoDome Inc., Atlanta, Georgia, USA)
with operating frequencies of 85 kHz, 174 kHz, and 1 MHz
were used. The 1-MHz transducer was calibrated using an
HNR-0500 hydrophone (Onda Corporation, Sunnyvale, Cal-
ifornia, USA), and the 85- and 174-kHz transducers were
calibrated using a TC4038 hydrophone (Reson Inc., Goleta,
California, USA). Calibration for each transducer was
performed in the Fresnel region of the US beam using the
lateral beam proﬁle at a distance of 0.42 cm from the face of
the transducer. Pressures and energy densities in this paper
are reported as spatial and temporal average values. A signal
generator (Agilent 33120A, Palo Alto, California, USA)
along with an ampliﬁer (CytoDome) was used to drive the
transducers. The electric power and signal waveform fed to
the transducers were continuously measured using an oscillo-
scope (Tektronix TDS 224, Beaverton, Oregon, USA). A
step-up tuning transformer (1:2.8) was connected in series
with each transducer to optimize its performance (Fig. 1). US
was applied in pulsed form at a constant burst rate
(100 bursts/s for 85- and 174-kHz transducers and 1 bursts/s
for 1-MHz transducer). The duty cycle was varied in the
range of 1% to 7%; however, for most sonication conditions, it
was ﬁxed at 5% unless otherwise stated. “Sham” exposure
experimentswerecarriedoutinthesameapparatuswithoutUS.
The US transducer, with a cross-sectional area of
2.54 cm
2, was secured in the donor compartment. US was
applied fora totalof4h at roomtemperatureinallexperiments.
Samples were collected from the receiver chamber at regular
intervals up to 4 h during the experiment (with or without US),
and tracer molecule concentration was determined using a
liquid scintillation counter (Packard, Meriden, Connecticut,
USA). At the end of 4 h, effective tissue permeability, P,w a s
obtained as follows:
P ¼
VR
ACD
dCR
dt
; ð1Þ
where VR is volume of the receiver chamber (1.02 cm
3), A is
brain cross-sectional area for transport (2.54 cm
2), CD is donor
concentration (1 µCi/mL), CR is receiver concentration, and t is
time. Permeation enhancement due to US exposure was
calculated by dividing P by its value in the absence of US.
Electrical conductivity measurements. Electrical conduc-
tivity (σ) of the brain tissue was measured during US
exposure as a surrogate measure for tissue permeability. A
potential (V) of 100 mV rms AC at 10 Hz was applied across
the tissue using a signal generator (Agilent 33120A). The
current (I) ﬂowing through the tissue was measured using a
multimeter (Fluke 189 True RMS Multimeter, Everett,
Washington, USA; Fig. 1). Conductivity was calculated as
follows:
  ¼ I=V ðÞ   L=A ðÞ ; ð2Þ
in which L is thickness of the tissue (2 mm) and A is cross-
sectional area (2.54 cm
2), assuming that the conductance at
10 Hz is the same as the DC conductance (23). Conductivity
enhancement due to US exposure was calculated by dividing
σ by its value in the absence of US.
Tissue histology. Brain samples were collected following
sonication at 85 kHz, 174 kHz, and 1 MHz frequency and at
an energy density of 1,250 J/cm
2. Control samples were also
collected from the tissues not exposed to US. Tissues were
ﬁxed in 10% formalin for 24 h and embedded in parafﬁn.
Five-micrometer-thick tissue sections were stained with
1006 Liu et al.hematoxylin-eosin for structural analysis (Mass Histology
Service, Worcester, Massachusetts, USA).
In Vivo Brain Delivery
We applied US through a craniotomy window in this
study to avoid the complexities of transmitting US through
the skull, which can be accomplished, for example, using low-
frequency, large surface area phased arrays and US wave
distortion correction methods (24,25).
US device. A custom-built US device for implantation
into the primate brain including a non-focused piezoelectric
1-MHz transducer was fabricated by CytoDome as shown in
Fig. 2a. The transducer was calibrated as described previ-
ously. The device was tested for magnetic resonance imaging
(MRI) compatibility and found compatible, so that the MRI
results would not be affected by the US device. Device
temperature as a function of emitted power was also tested,
and the US conditions that did not affect the temperature
change (i.e., <<1°C) were chosen: pressure of 1.24 MPa
(mechanical index (MI)=1.24), pulse length of 20 μs, and duty
cycle of 2.5%. A polyimide tube was inserted in the middle of
the transducer for liposome injection.
Liposome preparation. As described previously (26),
liposomes containing MRI contrast agent were composed of
1,2-dioleoyl-sn-glycero-3-phosphocholine (Avanti Polar Lip-
ids, Alabaster, Alabama, USA), cholesterol (Calbiochem, San
Diego, California, USA), and 1,2-distearoyl-sn-glycero-3-
[methoxy(polyethylene glycol)-2000] (PEG-DSG; NOF Cor-
poration, Tokyo, Japan) with a molar ratio of 3:2:0.3. The
lipids were dissolved in chloroform/methanol (90:10v/v) and
then the solvent was removed by rotary evaporation, result-
ing in a thin lipid ﬁlm. The lipid ﬁlm was dissolved in ethanol
and heated to 60°C. A commercial United States Pharmaco-
peia solution of 0.5 M Gadoteridol (10-(2-hydroxy-propyl)-
1,4,7,10-tetraazacyclododecane-1,4,7-triacetic acid; Prohance;
Bracco Diagnostics, Princeton, New Jersey, USA) was heated
to 60°C and injected rapidly into the ethanol/lipid solution.
Unilamellar liposomes were formed by extrusion (Lipex;
Northern Lipids, Vancouver, British Columbia, Canada) with
15 passes through double-stacked polycarbonate membranes
(Whatman Nucleopore, Clifton, New Jersey, USA) with a
pore size of 100 nm, resulting in a liposome diameter of 124±
24.4 nm as determined by quasi-elastic light scattering
(N4Plus particle size analyzer, Beckman Coulter, Fullerton,
California, USA). Unencapsulated Gadoteridol was removed
with a Sephadex G-75 (Sigma, St. Louis, Missouri, USA) size-
exclusion column eluted with pH6.5 HEPES-buffered saline
(5 mM HEPES, 135 mM NaCl, pH adjusted with NaOH).
Liposomes loaded with rhodamine for histological stud-
ies were formulated using the same lipid composition and
preparation method as the Gadoteridol-containing liposomes,
Fig. 1. In vitro brain slice permeability experimental setup containing (a) electrical conductivity measurement apparatus
to determine brain slice conductivity, (b) the US application and permeability measurement apparatus to expose brain
tissue to US and measure changes in tissue permeability to various molecules, and (c) the US waveform generation
apparatus to control US conditions
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sulforhodamine B (Sigma) in pH6.5 HEPES-buffered saline
bysixsuccessivecyclesofrapidfreezingandthawingratherthan
by ethanol injection. The sulforhodamine B liposomes had a
diameter of 90±30 nm (used alone for histological analysis) or
115±40 nm (used for co-infusion with the Gadoteridol-contain-
ing liposomes in the MRI-monitoring study).
Experimental subject and implantation. The experimen-
tal protocol was reviewed and approved by IACUC at the
University of California San Francisco (UCSF). A cynomol-
gus monkey (Animal F21339M, male, 6.5 kg) was identiﬁed
as a suitable liposomal infusion candidate (26) and received a
baseline MRI scan to generate surgical coordinates. Intra-
cranial procedures were performed to implant MRI compat-
ible guide cannula within the corona radiata. A 26G MRI
compatible guide cannula (26) was stereotactically introduced
into the right hemisphere (32 mm anterior from the ear canal,
10 mm lateral to midline, and a depth of 10 mm ventral to the
cortex). The left hemisphere received the US device with
guide cannula using the same coordinates. Each device was
secured to the skull using dental acrylic (Lang Dental
Manufacturing, Wheeling, Illinois, USA; Fig. 2b).
MRI acquisition and volume quantification. MR images
were acquired in collaboration with the UCSF Magnetic
Resonance Imaging Science Center (MRSC). As described
previously (26), T1-weighted images of the primate’s brain
were acquired on a 1.5-T Signa LX scanner (GE Medical
Systems, Waukesha, Wisconsin, USA) with a 5-in. surface coil.
Prior to inserting infusion catheters, baseline spoiled gradient
echo (SPGR) images were taken: repetition time/echo time/ﬂip
angle=28 ms/8 ms/40°, number of excitations=4, matrix=256×
192, ﬁeld of view=16 cm×12 cm, and slice thickness=1 mm.
These parameters resulted in a 0.391-mm
3 voxel volume. Once
the catheters were inserted and the infusion commenced,
SPGR scans were taken consecutively throughout the infusion.
The scan time was dependent on the number of slices needed
to cover the extent of infusion but was approximately 10 min.
The volume of liposomal distribution during and after infusion
Fig. 2. In vivo delivery experimental setup. a Schematic of US device with infusion cannula for in vivo
study. b Schematic of the experimental setup for liposomal distribution, where US was applied to the left
hemisphere and not to the right hemisphere
1008 Liu et al.was quantiﬁed by subtracting the infusion baseline images
from the ﬁnal infusion images and removing the background
intensities in the brain. The image was segmented for
liposomal distributions by a contouring function (iPlan Flow
software, BrainLAB, Westchester, Illinois, USA) that created
a region of interest for the calculation of the distribution
volume, Vd (26).
Liposome infusion. After a 4-week surgical recovery
period after device placement or between study sessions, the
animal was sedated, placed in a transport box, and trans-
ferred to the MRSC. Under isoﬂurane anesthesia, the
animal’s head was positioned in an MRI-compatible stereo-
tactic frame. The animal was transferred into the gantry of
the 1.5-T Signa LX scanner. After a pre-infusion MRI scan,
two non-ferromagnetic needle cannulas (26) (connected to
beehive micro-infusion pumps; Bioanalytical Systems, West
Lafayette, Indiana, USA) were aseptically introduced into
targeted regions of the brain using the implanted guide
cannula entry ports. Infusion procedures were initiated
simultaneously in two sites of the brain while MRI was
continuously acquired. An initial infusion rate of 0.1 µL/min
was applied and increased at 10-min intervals to a maximum
rate of 3.0 µL/min. After 30–50 µL of liposomes was
delivered, the infusion rate was ﬁxed at 3.0 µL/min for trial
I and 0.1 µL/min for trials II and III in both hemispheres to
maintain positive pressure, and an MRI scan was acquired to
verify adequate gd-lipo distribution into the corona radiata.
US was administered on the left hemisphere at several time
points during infusion and at the completion of infusion. MRI
was acquired prior to and immediately following each US
session. At the completion of the study, the animal was
removed from the MRI gantry, extubated, monitored for full
recovery from anesthesia, placed in its transfer cage, and
transported back to the animal facility.
Necropsy and histology. After all study sessions were
completed, the animal was transported to the necropsy room
and euthanized with an overdose of pentobarbital (IV). The
brain was harvested and coronally sliced into 9-mm blocks.
Each tissue block was freshly frozen in dry-ice cooled
isopentane and processed for histology. Relevant blocks
containing gadolinium and rhodamine infused sites were
sliced into 300-µm sections on a microtome and mounted
onto slides for microscopy.
In Vitro Safety and Drug Bioactivity
Cell culture. Rat cortical neurons were freshly harvested
from fetal E18 Sasco Sprague-Dawley rats (Charles River
Laboratories, Wilmington, Massachusetts, USA) with
IACUC approval as previously described (27)a n d
suspended in Neurobasal medium containing 2% B-27 and
500 μM L-glutamine (Gibco, Invitrogen, Carlsbad, California,
USA) at a concentration of 1×10
6cells/mL. DU145 human
prostate cancer cells (American Type Culture Collection,
Manassas, Virginia, USA, item no. HTB-81) in RPMI-1640
medium and human HT-1080 ﬁbrosarcoma cells (American
Type Culture Collection, item no. CCL-121) in DMEM
medium were cultured as monolayers in a humidiﬁed
atmosphere of 95% air and 5% CO2 at 37°C. The medium
was supplemented with 10% heat-inactivated fetal bovine
serum (FBS; Atlanta Biologicals, Atlanta, Georgia, USA)
and 1% penicillin/streptomycin (Cellgro, Mediatech, Herndon,
Virginia, USA).
US apparatus and exposure. To generate a range of
acoustic pressures for a broad assessment of possible damag-
ing effects of US, a focused 1.1-MHz transducer (model no.
H-101, Sonic Concepts, Woodinville, Washington, USA) was
submerged in de-ionized water at 37°C to sonicate a 375-μL
sample held within a disposable micropipette (Samco, San
Fernando, California, USA), as described previously (28).
The transducer was calibrated by a PVDF membrane hydro-
phone (NTR Systems, Seattle, Washington, USA, model no.
HMA-0200) at 1 cm from the transducer. Sonication was
carried out at pressures (p) ranging from 0 MPa (i.e., “sham”
exposure) to 2 MPa, and the total treatment time (t) was
either 10 or 60 min with a burst length of 750 μs at a 2.5%
duty cycle (D). Therefore, the corresponding energy density
(J) ranged from 0 to 12,000 J/cm
2, which was calculated as
J ¼ t   D  
pﬃﬃ
2
p
   2
    u
; ð3Þ
where ρ is the density of water (1 g/mL) and u is the speed of
sound in water (1,500 m/s).
Samples exposed to US included plasmid DNA, siRNA,
adeno-associated virus, and neuronal cells. DNA samples
were prepared by diluting plasmid gWizTM-GFP (Aldevron,
Fargo, North Dakota, USA) that encodes green ﬂuorescent
protein (GFP) to a ﬁnal concentration of 16 μg/mL in Opti-
MEM medium (Gibco). Survivin-siRNA (Silencer pre-
designed siRNA, Ambion, Austin, Texas, USA) was diluted
to a ﬁnal concentration of 100 nM in Opti-MEM medium.
Adeno-associated virus (provided courtesy of Dr. Atha-
nasios Sambanis, Georgia Institute of Technology, Atlanta,
Georgia, USA), prepared as described previously (29), was
diluted in DMEM medium supplemented with 2% FBS to a
concentration of 1.4×10
6infectious units/mL.
Rat cortical neurons were suspended in DMEM at a
concentration of 1×10
6cells/mL. Deﬁnity US contrast agent
(Lantheus Medical Imaging, North Billerica, Massachusetts,
USA) was added to some samples at a concentration of 0.2 vol.
% to serve as cavitation nucleation sites.
Sample analysis. Possible damaging effects of US were
assessed by measuring possible reductions in DNA’sa b i l i t yt o
transfectcells,siRNA’sabilitytoknockdownproteinexpression,
adeno-associated virus’ ability to transduce cells, and cortical
neuron viability after sonication. To measure DNA transfection
efﬁciency,DU145cellsweremixedwithsonicatedplasmidDNA
andLipofectamine2000(Invitrogen)accordingtotheprocedure
recommended by the manufacturer. After incubation in the
growth conditions in full culture medium for 24 h, cells were
trypsinized, suspended in 300 μL PBS, and placed on ice until
analysis by ﬂow cytometry (BD LSR, Becton Dickinson, San
Jose,California,USA).Transfectionefﬁciency was measured by
determining the percentage of cells with green ﬂuorescence due
to GFP expression greater than untreated control cells.
To measure survivin knockdown, DU145 cells were
transfected with sonicated siRNA using Lipofectamine 2000,
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full culture medium for 48 h, cells were trypsinized and
washed with 500 μLP B S .Aﬂuorescein isothiocyanate
(FITC)-labeled anti-survivin monoclonal antibody (R&D
Systems, Minneapolis, Minnesota, USA) was used to label
the target protein according to the procedure recommended
by the manufacturer. Survivin knockdown efﬁciency was
quantiﬁed by measuring the decrease in mean FITC ﬂuo-
rescence by ﬂow cytometry.
To measure adeno-associated virus transduction efﬁciency,
sonicated adeno-associated virus samples were incubated with
HT-1080 ﬁbrosarcoma cells (29). Brieﬂy, a 375-μL sample of
sonicated adeno-associated virus and 625 μL DMEM medium
supplemented with 2% FBS were added to HT-1080 cells
previously incubated for 1 day in six-well plates. After
incubation at 37°C for 1 to 2 h, 1 mL pre-warmed DMEM
medium supplemented with 18% FBS was added per well. Cells
were then incubated and analyzed by ﬂow cytometry, as
described above. Transduction efﬁciency was measured by
determining the percentage of cells with green ﬂuorescence
due to GFP expression greater than untreated control cells.
To measure cell viability, propidium iodide (Molecular
Probes, Eugene, Oregon, USA) was added to sonicated rat
cortical neurons at a concentration of 1 vol.% 5 min after
sonication. Cell viability was measured by determining the
percentage of cells lacking red ﬂuorescence due to propidium
iodide staining compared to untreated control cells (28).
Statistical Analysis
Analysis of variance and Student’s t test were applied to
the data. A value of p<0.05 was interpreted as signiﬁcant. All
data are reported as the mean ± the standard deviation.
RESULTS
This study was designed to broadly assess the ability of
US to enhance transport and distribution of drugs in the
brain. More speciﬁcally, we tested: (a) to enhance transport of
large molecules across brain tissue in vitro, (b) to validate in
vitro ﬁndings by examining the effect of US on transport in
the monkey brain in vivo, and (c) to validate that the US
conditions used in this study do not damage brain tissue or
the therapeutic molecules being delivered to the brain.
In vitro Brain Delivery
Relationship between sonication parameters and tissue
permeability. We ﬁrst tested the general hypothesis that US
increases the permeation of molecules across brain tissue. In
support of this hypothesis, Fig. 3a shows that US signiﬁcantly
enhanced mannitol transport across porcine brain tissue in
vitro (p<0.05 for all US settings compared to control).
Consistent with previous ultrasonic drug delivery studies in
other tissues (23), mannitol transport enhancement shows a
good correlation with ultrasonic energy density for each
frequency (Fig. 3a). The various energy densities were
achieved by applying US at different pressures and different
duty cycles at a constant exposure time of 4 h. Additional
statistical analysis showed that permeability enhancement
also increased with increasing pressure and increasing duty
cycle (p<0.05). The highest enhancement of 24-fold was
observed at an energy density of ∼1,200 J/cm
2 at a frequency
of 85 kHz. At a given energy density, the enhancement
decreased with increasing frequency (p<0.05). The
enhancement of mannitol transport at a constant energy
density (1,500 J/cm
2) for three frequencies is shown in Fig. 3b.
Fig. 3. In vitro brain slice permeability enhancement at different US conditions. a Variation of normal
porcine brain tissue permeability enhancement as a function of the energy density of the transducer at
three different US frequencies—85 kHz (circle), 174 kHz (square), 1 MHz (triangle). The lines show linear
regressions of the data (r
2=0.99 (1 MHz), 0.96 (174 kHz), 0.80 (85 kHz), n=3 replicates). All data points
are signiﬁcantly different from the non-sonicated control (p<0.05). b Variation of the permeability
enhancement as a function of US frequency at a constant energy density (1,500 J/cm
2). Data are taken
from a. Each of the data points is signiﬁcantly different from each other (p<0.05). Enhancement values are
determined relative to permeability of non-sonicated tissue
Liu et al. 1010An enhancement of 10.14-fold in mannitol transport was
observed at 85 kHz, which decreased to 4.87-fold at 1-MHz
US exposure.
Relationship between electrical conductivity and perme-
ability. US canincreasepermeationacrossbraintissuebyacting
on the molecule to provide a driving force for transport and by
acting on the tissue to increase its permeability. To assess the
role of the latter component, we measured brain tissue
conductivity during sonication, which is a measure of tissue
permeability and should not be inﬂuenced by US effects on the
molecule. This analysis showed that enhancement in mannitol
transport was accompanied by an increase in electrical con-
ductivity of the brain tissue. In the absence of US, the tissue
possessed a very low electrical conductance (0.45×10
−4–1.12×
10
-4S/m) which, upon sonication, increased quickly and
plateaued after about 2 h (1.97×10
−3–2.36×10
−3S/m).
Electrical conductivity enhancement, measured relative to the
controls at the end of the 4 h sonication period, correlated well
with the corresponding mannitol permeability enhancement
(Fig. 4, r=0.94 for linear ﬁt). This linear relationship between
permeability enhancement and conductivity enhancement was
true for all of the frequencies and energy densities reported in
thisstudy,whichsuggestsanimportantroleforUSeffectsonthe
tissue to increase its permeability.
Transport across brain tumors. For possible applications
to treat brain cancer, we exposed human brain 9-L tumor
tissue explanted from rats to 1-MHz US at an energy density
of 5,000 J/cm
2. Under these conditions, the passive
permeability (7.20±0.63×10
−5cm/min) of the tumor-bearing
tissue was increased by approximately 2.5-fold to a ﬁnal
permeability of 1.82±0.19×10
−4cm/min at the end of the 4-h
sonication (p=0.03; Fig. 5).
Dependence of permeability on molecular weight. Because
different brain therapies may require drugs and biotherapeutics
ofdifferentsizes,thedependenceofbraintissuepermeabilityon
molecular weight was tested using four hydrophilic solutes:
water (18 Da), mannitol (180 Da), inulin (5 kDa), and dextran
(70 kDa; Fig. 6a). In the absence of US, brain permeability
exhibited a strong size selectivity (p<0.05). Permeability
decreased byabout44-fold asthemolecular weightofthesolute
increased from 18 Da (water) to 70 kDa (dextran). Water had a
muchlargerpermeability(8.42×10
−5cm/min),whereasthethree
larger solutes had similar permeabilities (∼2×10
−6cm/min).
Upon application of US, tissue permeability to all four
molecules increased by 2.3- to 8.8-fold (p<0.05), and the
permeabilities of each molecule were statistically different
from each other (p<0.05). Similar to passive permeabilities,
ultrasonic permeability decreased by about 43-fold as the solute
molecular weight increased from 18 Da (water) to 70 kDa
(dextran).
We also examined brain tissue permeability to a lipophilic
drug—BCNU, which is used to treat brain cancer. BCNU (MW
∼214 Da) exhibited a passive permeability of 1.90±0.90×10
−6
cm/min in porcine brain tissue (Fig. 6b), which was statistically
indistinguishable from a hydrophilic molecule of similar size
(mannitol, 180 Da, 3.51±1.97×10
−6cm/min; p<0.05). US
enhanced brain permeability to BCNU by 2.8-fold to 5.80±
1.24×10
−6cm/min(p=0.007).BCNUpermeabilityenhancement
was signiﬁcantly less than mannitol enhancement (p=0.016).
Although BCNU and mannitol are of similar molecular
weight, higher lipophilicity of BCNU (logP=1.5) than
mannitol (logP=−3.1) suggests that transport pathways
opened up by sonication are aqueous in nature and thereby
preferentially enhance transport of hydrophobic molecules.
Histology. As a preliminary test of safety, histological
examination conﬁrmed that a moderate exposure to US
(85 kHz, 174 kHz, and 1 MHz; 1,250 J/cm
2) did not induce
physical structural changes at the microscopic scale in the
non-viable porcine brain tissue. All brain sections (control
and treated) appeared intact with minimal cellular distortions
(data not shown). There were no differences between the
Fig. 4. In vitro electrical conductivity enhancement plotted against
transport permeability enhancement for normal porcine brain tissue
under the inﬂuence of US (Pearson’s product-moment correlation
coefﬁcient, r=0.94 for linear ﬁt) at 85 kHz (circle), 174 kHz (square),
and 1 MHz (triangle). Permeability data were taken from Fig. 2a (n≥
3 replicates)
Fig. 5. Mannitol permeability values in normal porcine brain tissue
and human brain 9-L ﬂank tumor tissue with and without US
exposure. The tissues were exposed for 4 h to 1-MHz US at 5% duty
cycle and a total energy density of 5,000 J/cm
2 (n=3 replicates): US
increased tissue permeability in normal porcine brain tissue (p=0.016)
and in human brain tumor tissue (p=0.03)
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structure and tissue integrity as observed by light microscopy.
In Vivo Brain Delivery
Effects of US on liposomal distribution. Based on these
in vitro ﬁndings, we next studied the ability of US to increase
transport in brain tissue in vivo using a cynomolgus monkey
model. Although lower-frequency US increased tissue
permeability to a greater extent in vitro, we chose to use
higher-frequency (i.e., 1 MHz) US for the in vivo study to
reduce the likelihood of cavitation, which is suppressed at
higher frequency, and to enable better spatial localization of
effects, which is enhanced at higher frequency. In this study,
gd-lipo were infused into the corona radiate using separate
cannulas on the left and right hemispheres of the brain, and at
speciﬁc times, 1-MHz US was applied at the site of infusion
on the left hemisphere. Distribution of the gd-lipo was
monitored over time by MRI. This in vivo study
administered gd-lipo to facilitate MRI imaging, even though
gd-lipo are much bigger than molecules examined in the in
vitro studies. Three trials were conducted sequentially on the
same cynomolgus monkey. Figure 7 contains representative
data showing how gd-lipo distribution volumes were
determined in the brain. Figure 7a displays an MRI series
from the posterior to the anterior brain, in which US was
applied to the left hemisphere. The bright white regions are
areas containing gd-lipo. Through computer image analysis,
the edges of the white regions were identiﬁed and stacked on
top of each other, as shown in Fig. 7b. A quasi-three-
dimensional representation is also shown in Fig. 7c. The
volume of these stacked images corresponded to the gd-lipo
volume of distribution, and the data were listed in Table I.
Signiﬁcant effect of US on gd-lipo distribution was observed
in trial II and trial III, but not trial I. The volume of
distribution increased by 121% in trial II and 54% in trial III
after three US sessions, which was much larger than the non-
sonicated control (48% in trial II and 36% in trial III).
Closer examination of coronal MR images acquired after
trial III revealed that the gd-lipo distribution beneath the US
device appeared ﬂatter and extended 2 to 3 mm further in the
anterior–posterior direction when compared to the non-
sonicated hemisphere. In addition, distribution of the gd-lipo
in the anterior–posterior direction beneath the US device was
enhanced from 9 mm (right) to 12 mm (left). The extent of
enhanced delivery as a result from US administration was
consistent with the second trial, which also showed a marked
difference in liposomal distribution when compared to
delivery without sonication.
Clinical assessments. Clinical assessments were per-
formed on a daily basis to evaluate changes in animal
behavior and monitor clinical signs following the ﬁrst US
trials. The animal tolerated the US procedure with no motor
deﬁcits or signs of adverse effects, although a transient
decrease in appetite was observed on the morning after the
US procedure that persisted over a 5-day period.
Necropsy and histology. Gross necropsy ﬁndings after
the completion of all three trials revealed evidence of
infection on the surface of the dura within proximity to each
cannula entry site, including minor infection at the site of the
invasive procedure. Coronal examination of each brain slice
showed evidence of liposomal rhodamine infusion into
cortical and subcortical areas proximal to the cannula site.
Evaluation of liposomal rhodamine distribution was consis-
tent with gadolinium MRI ﬁndings. Further qualitative micro-
scopic evaluation showed that liposomal rhodamine uptake in
the US-treated hemisphere was homogeneously dispersed
over a wide region at the cannulated site (Fig. 7d). All normal
Fig. 6. In vitro brain slice permeability to different molecules. a Variation of normal porcine brain tissue
permeability as a function of the molecular weight of the molecule being transported under passive (empty circle)
and sonicated (filled circle) conditions. Sonication was carried out at 1 MHz, 5% duty cycle for 4 h at a total energy
density of 5,000 J/cm
2 (n=3 replicates). For each molecule, permeability during sonication was greater than under
passive conditions (p≤0.05). b Dependence of permeability to mannitol and BCNU under passive (black bar)a n d
sonicated(stripedbar)conditions.Sonicationwascarriedoutatthesameconditionsasina(n=3replicates).Permeability
was greater during sonication compared to passive conditions for mannitol (p=0.016) and BCNU (p=0.007)
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inﬂammatory cells within the affected zone, demonstrated
uniform staining characteristics. The tissue immediately
adjacent and beyond the rhodamine positive were normal
and devoid of ﬂuorescence. In comparison, the non-sonicated
site demonstrated similar rhodamine ﬂuorescence but within
narrow conﬁnes of the cannula tract. However, the staining
intensity was comparable to the treated region.
In Vitro Safety and Drug Bioactivity
To evaluate the possibility that US exposure can
adversely affect the integrity and, therefore, the bioactivity
of various therapeutic agents, we carried out studies to
examine the effects of US on the integrity of plasmid DNA,
siRNA, and a viral vector. We selected these models because
they are of interest to gene-based therapies and might be
more sensitive to damage by US compared to, for example,
small molecule drugs like BCNU. Possible damage to neuro-
nal cells, cultured in vitro, by US exposure was also examined
to supplement the in vivo pre-clinical study.
To assess whether US damages DNA, we exposed
plasmid DNA encoding GFP to US over energy densities
ranging from 0 to 12,000 J/cm
2. We selected this range of US
conditions because it included and well exceeded those found
to be useful for enhanced delivery in vitro and in vivo in the
previous sections. After sonication, the DNA was transfected
into cultured cells using a lipid transfection agent as an
assessment of DNA integrity. There was no signiﬁcant
difference in transfection efﬁciency between DNA sonicated
at any of the conditions tested compared to non-sonicated
controls (p>0.05) as shown in Fig. 8a. Note that sonication
was not used in this study to aid, for example, DNA entry
into cells, as has been reported before (30). The goal of this
safety study was to determine if sonication damaged DNA in
some way that affected subsequent transfection of cells.
A similar experiment was carried out to assess the effects
of US on the ability of siRNA to knock down expression of a
model protein, survivin. As shown in Fig. 8b, there were no
signiﬁcant differences in the level of protein knockdown
between siRNA sonicated at any of the conditions tested
compared to non-sonicated controls (p>0.05).
The effects of US on function of an adeno-associated
virus are shown in Fig. 8c. Over the range of conditions
examined, there were no signiﬁcant differences in the level of
transduction efﬁciency between sonicated adeno-associated
virus and non-sonicated controls (p>0.05), indicating the
integrity of virus was not affected by US.
Finally, the effect of US on the viability of cortical
neurons freshly harvested from fetal rats was examined. As
shown in Fig. 8d, sonication at pressures up to 1.5 MPa for up
to 60 min (energy density 6,750 J/cm
2) had no signiﬁcant
effect on neuronal cell viability (p>0.05), which is consistent
with the previous histology study. However, cell viability was
decreased when the acoustic pressure was increased to the
highest energy density of 12,000 J/cm
2, which caused cell
viability to decrease by 19% (p=0.0013). As a positive
control, sonication was carried out at 2,000 J/cm
2 in the
presence of Deﬁnity® US contrast agent, which served to
nucleate cavitation activity. Under these conditions, cell
viability was reduced by 35% (p=0.0006). However, the
conditions that caused losses of cell viability are much
stronger than the ones found to be useful for enhanced
delivery in the previous sections.
DISCUSSION
Previous studies have addressed ultrasonic drug delivery
into and across various tissues (13–16) including breaching
Fig. 7. Distribution of liposome in the non-human primate brain. a Illustrative MRI series (parallel coronal slices, from the upper left to the
lower right, posterior to anterior) showing gd-lipo distribution after the third US session in trial II. The presence of gd-lipo is indicated by white
coloring in the left sonicated hemisphere and the right non-sonicated hemisphere. b, c Graphical superposition of the areas of gd-lipo
distribution to create a quasi-three-dimensional image of the volume of gd-lipo distribution. d Low and high magniﬁcation of a representative
histology slide from the left hemisphere (US treated) showing rhodamine-loaded liposome infusion within and between the neuronal cells
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barrier into the brain (31,32). In this study, using in vitro and
in vivo analysis, we provide a detailed assessment of the
ability of US to further enhance drug transport and distribu-
tion in the brain from a macroscopic tissue-level perspective.
We quantify bulk transport of drugs in the brain tissue by
placing an US transducer directly in contact with the tissue to
enhance localized tissue permeability. In the in vitro experi-
ments, a signiﬁcant increase in drug transport across brain
tissue was found to occur over a broad range of US
conditions; however, the degree of transport enhancement
achieved was strongly dependent on US parameters. The
enhancement increased proportionally with the energy den-
sity and inversely with the frequency. Such dependencies are
consistent with previous observations on ultrasonic drug
delivery to cells and tissues other than the brain (16,33). In
particular, the inverse dependence of drug permeability on
frequency suggests the role of US-induced acoustic cavitation
in transport enhancement. The primary effect of US waves is
to physically perturb the material medium of passage, causing
the exposed material to vibrate at an amplitude dependent on
the material’s compressibility. For densely packed materials
such as brain tissue, US is expected to produce low displace-
ment, but for compressible gas bubbles or cavities in the
unconstrained saline bathing the brain tissue in vitro, US may
result in high displacements and strains yielding to cavitation.
This suggests that within the in vivo brain, where there is no
saline bath, cavitation should occur to a lesser extent.
Because the induction of cavitation is associated with
increased risk of mechanical damage to brain tissue, higher
ultrasound frequency exposure (1 MHz) was preferred in the
in vivo experiments of this study to further minimize this risk.
In principle, ultrasound may increase drug transport
across brain tissue by exerting convective forces on drugs or
by increasing the permeability of the brain tissue itself. Since
electrical conductivity, a measure of tissue permeability,
correlated well with drug transport, it suggests that US chieﬂy
affects the brain tissue and thus its permeability to drugs.
Upon US treatment, the magnitude of increase in brain tissue
conductivity (∼10- to 50-fold) was similar to the increase in
mannitol tissue permeability (up to ∼25-fold). Consistently,
the relationship between mannitol transport enhancement
and electrical conductivity enhancement was independent of
the ultrasonic frequency and energy density, suggesting a
lesser role of ultrasonic convective forces. Solute permeability
across the brain tissue decreased with increasing solute size.
The presence of a strong size dependence also suggests that
solute transport during US application may be mediated by
diffusion as opposed to convection.
US at 1 MHz also enhanced mannitol transport across
human brain tumor tissue excised from the rat ﬂank. Passive
permeability of the tumor tissue was about 20-fold higher
than that of the normal tissue. High tissue permeability
correlates well with increased diffusivity of solutes in the
tissue interstitium, which is consistent with several literature
reports documenting increased drug diffusivity in tumors (34).
The tumor interstitial compartment is characterized by large
interstitial space, high collagen concentration, low proteogly-
can, and hyaluronate concentrations leading to a high
interstitial diffusion coefﬁcient for a variety macromolecules—
up to an order of magnitude higher compared to normal
tissues (34,35). As such, US exposure can increase brain
tissue permeability by potentially expanding the tissue
interstitium. Ultrastructural studies have reported on US-
Table I. Distribution Volume of gd-lipo and the Volume Change in Both Hemispheres During US Exposure
Volume (μL) Volume change
a
Left (sonicated) Right (non-sonicated) Left (sonicated; %) Right (non-sonicated; %)
Trial I
Before US sessions 33 45
After 1st 30-min US session 38 58 15 29
After 2nd 30-min US session 95 146 188 224
After 16 h 279 310
After 60-min US session 254 235
After 10 min 229 220
Trial II
Before US sessions 82 65
After 1st 30-min US session 101 65 23 0
After 2nd 30-min US session 114 84 39 29
After 200-min “rest” session and
additional 20-μL infusion
158 91 93 40
After 3rd 60-min US session 181 96 121 48
After 16 h 119 82
After 60-min US session 124 60
Trial III
Before US sessions 241 269
After 1st 60-min US session 328 295 36 10
After 2nd 60-min US session 364 341 51 27
After 3rd 60-min US session 371 367 54 36
US exposure conditions—1.24 MPa (MI=1.24), pulse length of 20 μs, duty cycle of 2.5%
US ultrasound
aThe volume change is calculated based on the comparison to the volume before US sessions.
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or dilate interstitium in tissues other than brain (36,37). Our
limited histological analysis did not reveal any structural
changes in the brain tissue treated with US; however, addi-
tional studies are needed to assess the brain ultrastructure (at
the nanometer length scale using electron microscopy) to
probe this hypothesis.
In addition to increasing transport of a number of model
compounds, US was shown to increase delivery of BCNU
across brain tissue. BCNU is a leading chemotherapeutic drug
used for the treatment of brain tumors (38). Its efﬁcacy is
believed to be limited in part by its poor transport and
distribution in the brain (39). The intracranial spatial
distribution of BCNU during chemotherapy is determined
by a complex interplay of a host of known and unknown
mechanisms including diffusion, convection, and permeation
through the vascular endothelium (40). Various experimental
and theoretical studies have shown that BCNU exhibits
limited penetration when delivered from an implanted depot
in the brain (41,42). The small penetration depths are thought
to originate from rapid clearance of BCNU into systemic
circulation owing to its high transvascular permeability. This
diffusion–elimination related drop in concentration cannot be
easily compensated for by increasing the BCNU concentrations
in the depot because of toxicity to the surrounding healthy
tissue. Accordingly, mechanisms to facilitate the distribution of
BCNU more evenly throughout the tissue surrounding the
primary tumor may improve therapeutic effectiveness of the
drug. Our results demonstrate that US can be potentially used
for this purpose.
Increased brain tissue permeability may result due to
perturbation of various anatomical barriers within the brain
Fig. 8. Effect of US exposure on plasmid DNA, siRNA, virus integrity, and cortical neuron viability. a Plasmid gWizTM-GFP and b survivin-
siRNA were sonicated and subsequently transfected to DU145 cells by Lipofectamine 2000. Each bar displays the average and standard
deviation of a the transfection efﬁciency normalized by the non-sonicated control DNA and b the survivin knockdown efﬁciency normalized by
the non-sonicated siRNA (n≥4 replicates). Percent survivin knockdown was determined based on survivin expression levels from cells without
siRNA transfection set equal to 0% protein knockdown. Student’s t test showed no signiﬁcant changes in a transfection efﬁciency and b
knockdown efﬁciency at any of the conditions tested relative to the non-sonicated control (p>0.05). c Adeno-associated virus was sonicated and
subsequently transduced to HT-1080 cells. Each bar displays the average and standard deviation of the transduction efﬁciency normalized by
non-sonicated control virus (n≥4 replicates). Student’s t test showed no signiﬁcant changes in transduction efﬁciency at any of the conditions
tested relative to the non-sonicated control (p>0.05). d Cortical neurons were sonicated at different US conditions and, in one case, in the
presence of Deﬁnity® US contrast agent. Each bar displays the average and standard deviation of the cell viability normalized by non-sonicated
control neurons (n≥4 replicates). Student’s t test showed no signiﬁcant changes in cell viability at any of the conditions tested relative to the
non-sonicated control (p>0.05), except at the conditions indicated: *p=0.016, **p=0.0013, ***p=0.0006
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ments were performed with excised brain tissue and may be
lacking in structural barriers that are only functional in a
living brain. Therefore, we carried out additional experiments
in a non-human primate in vivo. To facilitate high-resolution
non-invasive MRI imaging, gadolinium-encapsulated lipo-
somes were used as a large model therapeutic that transports
poorly in the brain and would beneﬁt from increased trans-
port using US. This study showed that the distribution volume
of the liposomes could be increased by US. This result was
consistent with in vitro results and with our hypothesis that
US can enhance transport within the brain in vivo. Although
the limited availability and cost of non-human primate studies
p e r m i t t e du st op r o v i d ein vivo data from only a few
experiments that each used somewhat different conditions,
future studies should be aimed at optimizing the US
parameters to build off these preliminary results.
This study also provided an initial assessment of the
safety of US exposure. Because of its non-invasive nature, US
has the potential to avoid tissue damage. This safety, under
other US conditions, is well established for clinical use of US
for diagnostic imaging and therapeutic heating (44). Histo-
logical examination of the in vitro brain tissues exposed to US
did not show gross tissue damage at any of the conditions
studied. Experiments in a non-human primate similarly found
no indications of damage from US. Although a transient
decrease in appetite was observed, no changes in animal vital
signs and animal health were observed during and after
sonication. Energy density of 1,250 J/cm
2 was chosen to
correspond to the maximum brain permeability enhancement
(24-fold at 85 kHz) observed in the in vitro study (Fig. 3). As
such, safety threshold for various mechanical bioeffects of US
has been reported to correlate well with the MI of ultrasonic
exposure. US exposure with MI<1.9 is generally regarded
safe in tissues other than the eye (45). Consistently, in the
present study, histological analysis of ultrasonic exposure at
MI between 0.40 to 1.37 in vitro and MI=1.24 in vivo revealed
no gross damage to the brain tissue. Exposure of US was
found to be well tolerated by cultured cortical neurons in
vitro. Speciﬁcally, viability of cortical neurons was unaffected
over most conditions. Sonication at the highest energy density
of 12,000 J/cm
2 signiﬁcantly reduced cell viability; however,
this energy level was well beyond the conditions found to be
effective for enhanced delivery.
As a secondary objective, we evaluated the potency of
US brain delivery not only to facilitate drug delivery into the
brain but also to preserve the biological activity of the drugs
delivered by it. The sonochemical effects of US such as
production of free radicals during cavitation events have been
demonstrated to change the activity of drugs (46). We carried
out experiments designed to assess the functionality of several
therapeutic biomolecules of interest after US treatment. This
study showed that exposure to US at any of the conditions
tested did not signiﬁcantly affect transfection efﬁciency of the
plasmid DNA, protein knockdown efﬁciency of the siRNA,
or transduction efﬁciency of the adeno-associated virus.
These studies suggest that there is a broad range of US
conditions that may be suitable for enhanced delivery to the
brain without damaging the integrity of plasmid DNA,
siRNA, adeno-associated virus, or cortical neurons. Addi-
tional in vivo studies will be needed, which eliminate the
artifacts of in vitro cells in suspension, such as increased shear
stress due to acoustic streaming and cavitational activity, and
the inability of cell culture models to fully mimic brain tissue
in vivo. Other studies, using different US conditions for
different, but related, applications in the brain, have also
assessed US safety (32).
CONCLUSIONS
The study demonstrates that US is capable of enhancing
the permeation of several molecules including BCNU
through brain tissue in vitro and increasing the distribution
volume of liposomes in the non-human primate brain in vivo.
Enhanced delivery can be achieved at conditions that did not
appear to damage the integrity of DNA, siRNA, adeno-
associated virus, cortical neurons, or tissues. Altogether, these
ﬁndings suggest that US may provide a useful tool to enhance
delivery of therapeutics in the brain.
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